Abstract: Formulations and methods of treatment and putative prevention for aging (anti-aging composition) and for diseases or conditions of all reactive oxygen species-dependant illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic performance of humans include resveratrol and two (2) or more of the following features or additional active ingredients: (1) slow release formulation of resveratrol; (2) pterostilbene; (3) quercetin; (4) fisetin, and (5) naringenin. Slow release is defined for the purposes of the present invention as releasing 95% of the active agent or agents in eight (8) hours through normal human gastrointestinal absorption.

Abstract: The present invention pertains to the beneficial fusibility of ubiquinone (CoQ10) into digestible carrier fats that are solid at room temperature. By melting the CoQ10 into a properly chosen digestible carrier fat(s), recrystallization and phase separation issues are solved and a substrate is supplied for improved action upon CoQ10 by bile acids and lipases. The art taught here allows for the production of CoQ10 products with superior bioavailability, better stability and shelf life, and utilization via tablets, capsules and other dry delivery modalities, either as a single ingredient or as part of complex formulations. This art also can be used to improve CoQ10 inclusion in a variety of soft gelatin capsule formulations.

Abstract: Wild Garlic (Bear's or Forest Garlic, Allium ursinum) can be combined with cultivated high-allicin garlic (Allium sativum) and extracts of the same to take advantage of the previously unknown synergism of preparations made from these two garlic species. There is a substantial cost savings over the use of pure, Wild Garlic and an elimination of the side effects found with the chronic ingestion of high levels of cultivated allicin-rich garlic (Allium sativum). The resulting combination has demonstrated benefits with regard to blood lipids regulation in individuals in need thereof that are two or more times that expected from the use of either garlic species taken singularly. Blood pressure regulating benefits are maintained or improved, the odor-causing potential of high-allicin garlic is reduced, and significant improvements are found in the areas of total, LDL, and VLDL cholesterol and triglycerides, benefits far beyond the merely additive. HDL cholesterol levels also are improved.

Abstract: The present invention provides stable encapsulated (?)-hydroxycitric acid (“HCA”) dosage unit forms, uses thereof, as well as and methods of making the same. In particular, HCA and the salts, esters and amides of HCA according to the invention are delivered via enteric vehicles, such as enteric-coated tablets, and also enteric and enteric-coated capsules and soft gelatin capsules (softgels). Enteric-coatings may be applied externally to the HCA-containing dosage unit form or, in the case of capsules and soft gelatin capsules, the enteric compound also may be incorporated into the gelatin shell to yield an HCA-containing dosage unit form of the invention. The HCA-containing compositions are protected against acid degradation, lactonization and undesirable ligand binding in select environments.

Abstract: The inventors have discovered that food and pharmaceutical compositions containing (?)-hydroxycitric acid, its salts, amides and esters can be employed for delaying gastric emptying and increasing receptive relaxation for preventing and treating diverse conditions. The invention provides for HCA-containing compound useful to delay gastric emptying and increase receptive relaxation for preventing and treating diverse conditions, e.g., stomach ulcers, portal hypertension, liver dysfunction, diabetes and obesity. The invention provides methods for delaying gastric emptying and increasing receptive relaxation in individuals. The invention also provides methods of preventing or treating disorders or conditions related to aberrant gastric emptying and receptive relaxation.

Abstract: The present invention provides stable encapsulated (?)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption.

Abstract: The inventor has discovered that supplementation with (?)-hydroxycitric acid, its salts and related compounds constitutes a novel means of inhibiting, reducing and regulating calcification of the blood vessels and other soft tissues and is useful for preventing, treating and ameliorating conditions involving soft tissue calcification. Such regulation offers benefits against arterial calcification and vascular diseases, osteoarthritis, rheumatoid arthritis, the calcification of surgical stints, such as those containing elastin. These benefits of HCA are especially pronounced with the use of the preferred salts of the acid, potassium hydroxycitrate and potassium-magnesium hydroxycitrate, and may be further potentiated by the use of a controlled-release form of the compound. The discovery that HCA has calcium-regulating effects in the soft tissues allows for the creation of novel and more efficacious approaches to preventing and ameliorating cardiovascular diseases, arthritis and a variety of other conditions.

Abstract: The invention teaches that supplementation with (?)-hydroxycitrate constitutes a novel means of modulating the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system and is useful for preventing, treating and ameliorating conditions involving the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system. The discovery that HCA has angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system-moderating effects allows for the creation of novel and more efficacious approaches to preventing and ameliorating conditions that arise from excessive ACE activity. These include cardiovascular diseases in general, heart failure, ventricular remodeling, ejection fraction issues, atrial fibrillation, and a wide variety of renal conditions. Other health conditions discovered to be influenced by the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system would similarly be expected to be influenced.

Abstract: The invention teaches that supplementation with (?)-hydroxycitrate constitutes a novel means of reducing inflammation and is useful for preventing, treating and ameliorating conditions involving inflammation. The discovery that HCA has inflammation-moderating effects allows for the creation of novel and more efficacious approaches to preventing and ameliorating cardiovascular diseases, cancer, arthritis and a variety of other conditions that involve excessive inflammation. Inasmuch as one element common to advancing years is an increased level of generalized inflammation, the invention further lends itself to reducing or delaying this aspect of aging, one factor in what is known as sarcopenia. Furthermore, this discovery makes possible the development of adjuvant modalities which can be used to improve the results realized with other treatment compounds while at the same time reducing the side effects normally found with such drugs.

Abstract: The inventor has discovered that (?)-hydroxycitric acid (including the forms of its various salts) is useful for treating and ameliorating cachexia, health-threatening catabolism and unhealthful weight loss, such as is characteristic of sarcopenia. The dosage will depend on factors such as the starting weight of the individual and the percentage of the calories in the diet derived from fats. On a 30 percent fat diet, an efficacious daily dosage for most individuals will be between 250 mg and 3 grams per day. It may prove beneficial to deliver the desired dosage only once per day, preferably prior to the noon meal. The weight-gain effects of HCA are compromised by the actions compounds such as caffeine and ephedrine, hence these should be avoided. Due to the biphasic characteristics of HCA, there is an obvious overlap between dosages that can lead to weight gain and the higher dosages that can lead to weight loss in those who are above their ideal body weights.